CARNITOR (levocarnitine) by Leadiant Biosciences is clinical pharmacology carnitor (levocarnitine) is a naturally occurring substance required in mammalian energy metabolism. First approved in 1986.
Drug data last refreshed 4h ago · AI intelligence enriched 2d ago
CARNITOR (levocarnitine) is a naturally occurring amino acid derivative that facilitates long-chain fatty acid entry into mitochondria for energy production. It is indicated for primary and secondary carnitine deficiency, including inborn errors of metabolism such as glutaric aciduria II, methylmalonic aciduria, propionic acidemia, and medium-chain fatty acyl-CoA dehydrogenase deficiency. The drug works by promoting excretion of toxic acylCoA compounds and reducing metabolic autointoxication in patients with fatty acid oxidation disorders.
Product approaching loss of exclusivity with modest commercial footprint; brand team likely focused on lifecycle management and transition planning rather than expansion.
CLINICAL PHARMACOLOGY CARNITOR (levocarnitine) is a naturally occurring substance required in mammalian energy metabolism. It has been shown to facilitate long-chain fatty acid entry into cellular mitochondria, thereby delivering substrate for oxidation and subsequent energy production. Fatty acids…
Worked on CARNITOR at Leadiant Biosciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Carnitine Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCARNITOR offers niche career opportunities in rare disease and metabolic specialty focused on patient access, reimbursement, and clinical support rather than growth marketing. The LOE timeline and small patient base mean roles emphasize operational efficiency, cost management, and specialized expertise over high-volume sales.